Blackrock, INC Schedule 13G passive stakes
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.4% of 1-800-FLOWERS.COM, Inc.'s Class A Stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.3% Passive Stake in ON24 Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% passive beneficial ownership stake in ON24 Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a beneficial ownership of 7.7% in Orthofix Medical Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.1% Passive Stake in Piedmont Lithium Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% passive beneficial ownership stake in Piedmont Lithium Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Puma Biotechnology Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.9% Stake in Q2 Holdings, Inc. Common Stock
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a beneficial ownership of 7.9% in Q2 Holdings, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.4% Passive Stake in Quest Diagnostics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Rayonier Advanced Materials, Disclosing 7.1% Passive Ownership
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.1% beneficial ownership stake in Rayonier Advanced Materials Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Red Violet, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.1% Stake in Relay Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Relay Therapeutics, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock, Inc. Discloses 15.3% Stake in SITE Centers Corp.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 15.3% beneficial ownership stake in SITE Centers Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in South Plains Financial, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Stake in Syndax Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Syndax Pharmaceuticals Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, disclosing a 7.7% beneficial ownership stake in VeriSign Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% passive beneficial ownership stake in Vertex, Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, reporting a 6.3% beneficial ownership stake in Willdan Group, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing a 6.7% passive beneficial ownership stake in Adaptive Biotechnologies Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 8.3% of Agilent Technologies Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% passive ownership stake in Akebia Therapeutics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.7% Stake in American Public Education Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in American Public Education Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in AngioDynamics Inc.
BlackRock, Inc. has filed an Amendment No. 8 to Schedule 13G, disclosing a 7.2% passive beneficial ownership stake in AngioDynamics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.7% Passive Stake in ANSYS Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.7% of ANSYS Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, reporting a 12.4% beneficial ownership stake in Astrana Health, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.8% beneficial ownership stake in AutoNation, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 5.7% Stake in Beyond Meat, Files Updated Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 5.7% of Beyond Meat, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 8.5% of Biogen Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing a 7.5% beneficial ownership stake in Builders FirstSource, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.9% Stake in Claros Mortgage Trust Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.9% in Claros Mortgage Trust Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock, Inc. Discloses 8.5% Passive Stake in Coherent Corp.
BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.5% beneficial ownership stake in Coherent Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 6.6% beneficial ownership stake in Coherus BioSciences Inc. as of March 31, 2025.